BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20428938)

  • 41. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
    Liang X; Briaux A; Becette V; Benoist C; Boulai A; Chemlali W; Schnitzler A; Baulande S; Rivera S; Mouret-Reynier MA; Bouvet LV; De La Motte Rouge T; Lemonnier J; Lerebours F; Callens C
    J Hematol Oncol; 2018 Oct; 11(1):124. PubMed ID: 30305115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.
    Zembutsu H; Suzuki Y; Sasaki A; Tsunoda T; Okazaki M; Yoshimoto M; Hasegawa T; Hirata K; Nakamura Y
    Int J Oncol; 2009 Feb; 34(2):361-70. PubMed ID: 19148470
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between breast cancer subtypes and response to neoadjuvant anastrozole.
    Dunbier AK; Anderson H; Ghazoui Z; Salter J; Parker JS; Perou CM; Smith IE; Dowsett M
    Steroids; 2011 Jul; 76(8):736-40. PubMed ID: 21447351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinicopathological and genomics predictors of response to neoadjuvant chemotherapy in breast cancer].
    Frati A; Lesieur B; Benbara A; Bezu C; Uzan S; Rouzier R; Coutant C
    Gynecol Obstet Fertil; 2010; 38(7-8):475-80. PubMed ID: 20579923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
    Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
    Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
    Lu Y; You M; Ghazoui Z; Liu P; Vedell PT; Wen W; Bode AM; Grubbs CJ; Lubet RA
    Cancer Prev Res (Phila); 2013 Nov; 6(11):1151-61. PubMed ID: 24067424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
    Ghazoui Z; Buffa FM; Dunbier AK; Anderson H; Dexter T; Detre S; Salter J; Smith IE; Harris AL; Dowsett M
    Clin Cancer Res; 2011 May; 17(9):3005-12. PubMed ID: 21325071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
    Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
    Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular effects of oestrogen deprivation in breast cancer.
    Miller WR; Larionov A
    Mol Cell Endocrinol; 2011 Jul; 340(2):127-36. PubMed ID: 21605624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.
    Miller WR; Larionov A; Anderson TJ; Walker JR; Krause A; Evans DB; Dixon JM
    Cancer; 2008 Feb; 112(3 Suppl):689-694. PubMed ID: 18072233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
    Glaser RL; Dimitrakakis C
    Menopause; 2014 Jun; 21(6):673-8. PubMed ID: 24149917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular changes in lobular breast cancers in response to endocrine therapy.
    Arthur LM; Turnbull AK; Webber VL; Larionov AA; Renshaw L; Kay C; Thomas JS; Dixon JM; Sims AH
    Cancer Res; 2014 Oct; 74(19):5371-6. PubMed ID: 25100562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.
    Chimge NO; Baniwal SK; Luo J; Coetzee S; Khalid O; Berman BP; Tripathy D; Ellis MJ; Frenkel B
    Clin Cancer Res; 2012 Feb; 18(3):901-11. PubMed ID: 22147940
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A case of an elderly breast cancer patient achieving partial response with toremifene without efficacy of letrozole as a preoperative primary endocrine therapy].
    Arai T; Ooshiro C; Kamigaki S; Miwa H; Yoneda G; Harada H; Furukawa H
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2627-9. PubMed ID: 22189230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer.
    Tsoi H; Lok J; Man EP; Cheng CN; Leung MH; You CP; Chan SY; Chan WL; Khoo US
    J Pathol; 2023 Oct; 261(2):156-168. PubMed ID: 37555303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.
    Selli C; Dixon JM; Sims AH
    Breast Cancer Res; 2016 Dec; 18(1):118. PubMed ID: 27903276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
    Ghimenti C; Mello-Grand M; Grosso E; Scatolini M; Regolo L; Zambelli A; Chiorino G
    Exp Ther Med; 2013 Mar; 5(3):902-906. PubMed ID: 23408108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of concern--validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
    Collingridge D
    Lancet Oncol; 2010 Sep; 11(9):813-4. PubMed ID: 20667781
    [No Abstract]   [Full Text] [Related]  

  • 59. Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
    Anurag M; Zhu M; Huang C; Vasaikar S; Wang J; Hoog J; Burugu S; Gao D; Suman V; Zhang XH; Zhang B; Nielsen T; Ellis MJ
    J Natl Cancer Inst; 2020 Jul; 112(7):737-746. PubMed ID: 31665365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aromatase inhibitors--gene discovery.
    Miller WR; Larionov A; Renshaw L; Anderson TJ; White S; Hampton G; Walker JR; Ho S; Krause A; Evans DB; Dixon JM
    J Steroid Biochem Mol Biol; 2007; 106(1-5):130-42. PubMed ID: 17616392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.